Associated Papers
Not too little, not too much: the impact of mutation types in Wiskott-Aldrich syndrome and RAC2 patients.
Hsu AP
Clinical and Experimental Immunology, 2023
Spatially interacting phosphorylation sites and mutations in cancer.
Huang KL et al.
Nature Communications, 2021
33875650 (PubMed )
Supplement: 41467_2021_22481_MOESM4_ESM.xlsx › TableS1.HybridClusters
RAC1 as a Therapeutic Target in Malignant Melanoma.
Cannon AC et al.
Trends in Cancer, 2020
RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance.
Lionarons DA et al.
Cancer Cell, 2019
31257073 (PubMed )
Supplement: mmc1.pdf
Comprehensive genomic profiling of high-grade serous ovarian carcinoma from Chinese patients identifies co-occurring mutations in the Ras/Raf pathway with TP53.
Zhong F et al.
Cancer Medicine, 2019
The role of Rac in tumor susceptibility and disease progression: from biochemistry to the clinic.
Casado-Medrano V et al.
Biochemical Society Transactions, 2018
The Rac GTPase in Cancer: From Old Concepts to New Paradigms.
Kazanietz MG et al.
Cancer Research, 2017
NRAS, NRAS, Which Mutation Is Fairest of Them All?
Grill C et al.
The Journal of Investigative Dermatology, 2016
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
Chang MT et al.
Nature Biotechnology, 2016
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.
Krauthammer M et al.
Nature Genetics, 2012
22842228 (PubMed )
Supplement: NIHMS390374-supplement-1.pdf
Select a paper to view details